Abstract
Introduction 62
Considerable progress has been made in elucidating the genetic basis of complex disease 63 traits. The associated genetic polymorphisms identified are usually relatively common in the 64 population and the risk alleles impart a modest individual increment to the likelihood of 65 developing disease. The allelic identities of such genetic factors are established using large-66 scale genotyping chips with a predetermined composition of tagging variants. Advances in 67 DNA sequencing technology, such as next-generation sequencing (NGS), enable the 68 characterization of rare and unique genetic variants. Targeting the exome, which comprises 69 approximately 1% of the genome, facilitates (by scale) analysis of NGS data and provides a 70 highly enriched source of highly penetrant disease causing mutations 1 . The impact of NGS 71 has been dramatic in monogenic disease; in a recent review it was stated that the genes 72 underlying approximately half of known Mendelian disorders had been discovered 2 . In 73 contrast, the role of rare genetic variants in complex diseases is unknown. It had been 74
proposed that rare variants might explain, at least in part, the missing heritability that is 75 frequently described in complex disease traits 3 . Yet very few examples of individual rare 76 variants contributing to complex disease risk have been identified 4 . However, rare variants 77 are collectively very common; indeed the Exome Aggregate Consortium (ExAC) have 78 demonstrated that the vast majority of genetic variation is extremely rare 5 . Therefore, as 79 opposed to case-control analyses on the variant-level -as routinely employed for common 80 polymorphisms -the contribution of rare variation can be assessed on the gene-level by 81 aggregating all observed rare variants in a defined region and performing burden tests. 82
Although there are examples of disease predisposition genes, typically identified through 83 genome-wide association studies (GWAS), harbouring associated variants across a 84 spectrum of allele frequencies 4, 6, 7 , studies focusing on canonical disease-associated loci 85 have been far from fruitful, suggesting these loci by and large do not harbour additional risk 86 through rare variation 8 . Exome-wide searches have similarly revealed limited numbers of 87 rare variation associated with complex diseases; a recent large-scale whole-exome 88 sequencing case-control study in Type 2 Diabetes concluded that rare variants do not play a 89 major role in disease predisposition 9 . Furthermore, widely used gene-based association 90 tests have been shown to lack power at the exome-wide level, even with sample sizes up to 91 10,000, suggesting the need for reduced number of tested regions 10 .
92
Our strategy to address this problem is outlined here and summarised in Fig. 1 . We selected 93 SLE cases with a severe phenotype (young age of onset and clinical features associated 94 with poorer outcome) and hypothesized that these individuals would exhibit unique mutation 95 events in their protein coding DNA that predisposed to disease risk. Therefore, we undertook 96 whole exome sequencing (WES) in 30 family trios (both parents and affected offspring) and 97 scrutinized the data for de novo mutations in the individual with SLE to identify a group of 98 candidate genes for an independent follow-up rare variant analysis. This method allowed the 99 identification of novel loci harbouring disease risk through collective rare variation. 
Results

118
Identification of de novo mutations in SLE cases 119
We screened for de novo mutations by WES of 30 family trios with an affected offspring with 120 more severe SLE (Supplementary Fig. 1 Fig. 2 ). These data fit with the estimation that each exome contains one de 126 novo mutation 11 .
127
We also analysed the SLE proband WES data alone, without the unaffected parents. This 128 revealed 1,194 non-silent, heterozygous, rare variants in 1,067 genes, which would make 129 prioritisation for downstream analysis a difficult task, highlighting the benefit of parent-130 offspring trio sequencing (Supplementary Fig. 3) . 131
Through Sanger sequencing all three members of the parent-offspring trio, plus any 132 additional unaffected siblings (Supplementary We explored the function, expression (BioGPS), known associations with autoimmunity 149 (ImmunoBase), and gene-level constraint against missense mutations (ExAC), of the genes 150 with de novo mutations to build a profile of a priori evidence of a role in SLE pathogenesis 151 ( Table 2 ). The candidate genes include autoimmune susceptibility genes (PRKCD, DNMT3A 152 and ANXA3), although none have been previously associated with SLE through GWAS in 153 any population 13, 14 . We also identify candidate genes through known/predicted function and 154 expression profiles (C1QTNF4, SRRM2, HMSD), and four genes (PRKCD, DNMT3A, 155 C1QTNF4 and LRP1) with a significant (Z>3.09) constraint against missense variants (Table  156 2). 157
158
Functional characterisation of de novo mutations 159
To analyse the potential impact of the de novo mutations, we used the ExAC database 5 and 160
Combined Annotation Dependent Depletion (CADD) scores 15 Using a collapsing burden test 16 , we surveyed each of the 14 genes for an excess of 179 aggregated rare (minor allele frequencies (MAF)<1%) exonic variants in SLE cases 180 compared to healthy controls, and we identify an association of rare exonic variation in 181 PRKCD with SLE ( Table 3 ; P=0.0028). In sub-phenotype analyses, using healthy controls 182 and only SLE cases with anti-dsDNA (ncases=1261) or renal-involvement with 183 hypocomplementemia (ncases=186), both of which are markers of more severe disease, we 184 identify collective rare exonic variants in DNMT3A associated with both anti-dsDNA (Table  185 3; P=0.0005) and renal involvement with hypocomplementemia ( Table 3 ; P=0.0033). We 186 also collapsed all exons from the 14 genes together to test for an overall burden of rare 187 variants across these loci. These analyses revealed no excess of rare exonic variants across 188 the grouped genes, reflecting the hypothesis that some/most genes will not be relevant to 189 disease status because the observed de novo mutations are random background variation 190
only. 191
Using gene-level constraint metric data from ExAC 
Common variant analysis across de novo mutation genes 199
Loci harbouring autoimmune risk through both common and rare variants have been 200 reported 6, 17 . Therefore, using the high-density UK10K-1000GP3 imputed data, we 201 reassessed the contribution of common variation to SLE risk across these loci. No significant 202 association at any locus was observed with overall risk in a case-control comparison, as 203 previously reported 13 , nor with anti-dsDNA (ncases=1261) or renal-involvement with 204 hypocomplementemia (ncases=186) sub-phenotypes (Supplementary Table 3 
Underfunctioning of C1QTNF4 p.His198Gln 210
The candidate gene C1QTNF4 is a very small gene with <1Kb coding sequence over two 211 exons and is one of four genes constrained against missense variants (ExAC gene-level 212 constraints Z=3.17, Table 2 ). Although gene coding length does not correlate with missense 213 constraint scores 5 , it may contribute to insufficient power to detect rare variant associations 214 when using imputed data derived from reference haplotypes from healthy individuals alone. 215
The de novo mutation in C1QTNF4 generates a His198Gln protein sequence change with a 216 modest CADD score of 12.3 ( Table 1) . Although they are useful in the absence of suitable 217 functional assays, the sensitivity of bioinformatic prediction tools is known to be suboptimal. 218
Where functional assays are available, previous studies have also demonstrated functional 219 effects of variants predicted to be tolerated/benign 19 . 220
We therefore pursued a functional analysis of the His198Gln de novo mutation detected in 221 the C1QTNF4 gene. Although its function is rather poorly understood, the protein product, 222 C1QTNF4 (CTRP4) is secreted and may act as a cytokine, as it has homology with TNF and 223 the complement component C1q (Fig. 2) . C1QTNF4 has been shown to influence NF-κB 224 activation 20 , a pathway known to be implicated in SLE pathogenesis. In order to study the 225 effect of the C1QTNF4 mutation, we looked for an effect on NF-κB production. Using a 226 HEK293-NF-κB reporter cell line, we showed that C1QTNF4 p.His198Gln mutant protein 227 was expressed and that it inhibited the NF-κB activation generated by exposure to TNFα 228 (Fig. 2) . Furthermore, we showed that the fibroblast L929 cell line, which is sensitive to TNF-229 induced cell death, was rescued by exposure to C1QTNF4 p.His198Gln, but not by wild type 230 C1QTNF4. Thus, the mutant form of C1QTNF4 appears to inhibit some of the actions of 231 TNF, which may promote antinuclear autoimmunity [21] [22] [23] . Following the unexplained heritability left in the wake of massive GWAS in most complex 266 diseases, searching the GWAS-identified canonical disease susceptibility genes for rare 267 variants has added little to the heritability explained. Although there are examples -and 268 perhaps more to discover -of canonical disease genes harbouring both common and rare 269 risk alleles, the vast majority of such loci do not 6 . Indeed the common-variant associated loci 270 which have also been shown to harbor rare coding variant risk are often those loci where the 271 common polymorphisms are non-silent coding variants (e.g. NCF2 8 ). Our data suggest that 272 rare genetic risk may be found in a discrete set of non-canonical susceptibility genes, as we 273 report an association of collective rare variation at PRKCD and DNMT3A, and found no 274 evidence of an association with common variants across these loci. This, to the best of our 275 knowledge, is the first WES study in polygenic cases of autoimmune disease to use de novo 276 mutation discovery to identify candidate genes for rare variant analyses. 277
We saw a relatively high drop-out rate (11.7%) from our NGS to Sanger sequencing 278 confirmed mutations due to the two variants -KRTAP10-2 and KLRC1 -found in members 279 of highly homologous gene families. This suggests our NGS error-prone genes (NEPG) filter, 280 which removes loci known to be problematic for genome mapping during NGS analyses, 281
should have been more conservative. 282 DNMT3A and PRKCD, although hitherto not associated with polygenic SLE, are known 283 autoimmunity susceptibility loci; DNMT3A is associated with Crohn's disease (CD) 24 and 284 PRKCD is associated with both CD and ulcerative colitis (UC) 25 . The notion that a locus 285 could harbour common variants contributing to one autoimmune disease and rare variants 286 contributing to another is intriguing, and could provide hypothesis-driven searches in the 287 hunt for 'missing heritability'. another member of the protein kinase C gene family, has been implicated in SLE risk in a 295
Chinese study 27 . 296 DNMT3A, a DNA methyltransferase, is a very intriguing candidate gene for SLE as altered 297 patterns of DNA methylation are reported in autoimmune diseases 28 , and hypomethylation of 298 apoptotic DNA has been reported to induce autoantibody production in SLE 29 . DNA 299 methylation changes are also associated with monozygotic twin discordance in SLE 30 . 300
Although previously implicated through a candidate gene study 18 , we found no evidence of a 301 common variant association at this locus. Instead we find an association of collective rare 302 variants and SLE sub-phenotypes. 303
Together with the results of Hunt et al., in which autoimmune cases were aggregated and 304 rare variants were found to play a negligible role 8 , our study suggests the importance of 305 deep phenotyping and the potential role of rare variants in specific sub-phenotype, or indeed 306 autoimmune, manifestations. Despite progress with diagnosis and treatment, particular SLE 307 sub-phenotypes -including those used in this study -are still associated with reduced life 308 expectancy. Therefore, elucidating the specific underlying genetic risk is of paramount 309
importance. 310
Our rare variant study is likely to be underpowered given the burden testing was conducted 311 on imputation data from an, albeit large, reference panel of healthy individuals and therefore 312 will not include putative SLE-specific variants. Therefore, other loci with suggestive p-values 313 at candidate genes (e.g. HMSD) warrant follow-up analyses through sequencing and/or 314 SLE-weighted imputation reference panels. 315
Through two in vitro assays, we demonstrated the functional effect of a de novo variant, 316
His198Gln in C1QTNF4, despite this variant being predicted to be of little functional 317 importance across multiple prediction tools. We showed the mutated protein product of 318 C1QTNF4, C1QTNF4, inhibits some TNF-mediated cellular responses, including activation 319 of NF-κB and TNF-induced apoptosis. The role of TNF in SLE is complex and incompletely 320 understood, although, in this context, it is noteworthy that TNF inhibition may promote 321 antinuclear autoimmunity 22 . A recent transancestral Immunochip analysis found an 322 association at the chromosome 5-encoded C1QTNF2 with SLE (Nature Communications, in 323 press), and chromosome 22-encoded C1QTNF6 is a known susceptibility locus for Type 1 324
Diabetes and is implicated in Rheumatoid Arthritis 31, 32 . Together these data suggest a 325 potential role of the hitherto understudied C1QTNF superfamily of genes in autoimmunity. 326
Each human -regardless of the disease status -is estimated to have one de novo mutation 327 in their exome 11 . The simple presence of a provisionally functional de novo mutation in a 328 proband is therefore not sufficient evidence that it contributes to disease risk. A major 329 challenge of WES studies, therefore, is how to differentiate between variants truly important 330 to disease and background variation 33 . In light of recent studies which have demonstrated 331 the limitations of large-scale exome-wide case-control studies in detecting rare variant 332 contributions 9, 34 , our results support extreme-phenotype sampling and de novo mutation 333 discovery to aid a hypothesis-driven search for rare variation contributing to the heritability of 334 complex diseases. 335
336
Methods 337
Selection of trios for sequencing 338
SLE patients of European ancestry were selected from the UK SLE genetic repository 339 assembled in the Vyse laboratory. The study cases have been subject to genome-wide 340 genotyping as part of a GWAS 13 . The criteria for inclusion were as follows: age of onset of 341 
Quality control (QC) and variant annotation 363
Variants were retained if they passed the following criteria: (i) read depth ≥20x, (ii) located 364 within exome-captured regions as annotated in Gencode (on-target) and NCBI RefSeq 365 annotation 35 . Read depth estimation was performed using DepthOfCoverage from GATK 366 tool 36 , as evaluated using bedtools 37 . All but one family had 75% representation of the 367 exome at 20X (Supplementary Fig. 1 ). Variants passing these QC criteria were annotated 368 using ANNOVAR 38 . Any variant observed in either ExAC, 1000 genomes, ESP6500, or in-369 house databases was considered polymorphic. We also further selected variants that did not contain any trace of alternate allele 393 in any of the parents. IGVtools was used to count the number of non-reference 394 bases at each identified variant position from both father and mother. Only 395 variants with a zero count of non-reference bases in both father and mother were 396 considered as very high quality variants and retained for further analysis. 397
3.
Variant annotation: only non-silent variants (Missense, Nonsense, splicing and 398 insertions/deletions) was retained for further analysis. 399
This process resulted in a total of 17 variants in 17 genes (Supplementary Table 1) . 400
Analysis of whole exome sequencing (WES) in cases only 401
To quantify the advantage of using parent-offspring trios, the whole exome samples of the 402 30 probands were analysed alone. 584,798 variants with ≥20X coverage depth and within 403
Gencode capture regions were identified. All stringent filters to help in refinement of variants 404 that could be potentially causal were applied. These include two filters previously described 405 in the de novo filtering approach (Non-NEPG and variant annotation) along with selection of 406 heterozygous variants (based on the pattern of zygosity expected for de novo mutations) 407 and non-polymorphic filters (variants not observed in control datasets). To note, this is unlike 408 the trio analysis where variants were not filtered for non-polymorphic. Filters were applied 409 sequentially 1) Non-NEPG 2) Variant annotation 3) Heterozygosity 4) Non-polymorphic and 410 resulted in 1194 variants in 1067 genes (Supplementary Figure 3) . 411
412
Sanger Sequencing confirmation 413
Primers were designed using Primer 3 to target the exon containing the de novo mutation. 414
Primers and PCR conditions available on request. 10ng of DNA from SLE probands, any 415 unaffected siblings and both parents was amplified with Hot Start Taq polymerase on a G-416 Storm Thermocycler. PCR products were first cleaned with EXO-SAP before BigDye 417 labelling in a linear PCR. Samples were sequenced on an ABI 3300XL. 418
419
Imputation 420
Genotype data from 10,995 individuals of matched European ancestry, including 4,036 SLE 421 cases, genotyped on the Illumina Chip Illumina HumanOmni1 BeadChip for a previous 422 study 13 were used. These data had undergone quality control as previously described imputation without pre-phasing was conducted using IMPUTE2 44, 45 . Imputed genotypes were 430 filtered for confidence using an info score (IMPUTE2) threshold of 0.3 (Supplementary 431 Figure 6 ). The most likely genotype from IMPUTE2 was taken if its probability was > 0.5. If 432 the probability fell below this threshold, it was set as missing. Variants with >10% missing 433 genotype calls were removed for further analysis. All individuals had <8% missing genotype 434
data. 435 436
Rare Variant Burden Tests 437
Imputed data were filtered, using Plink v1.9, to include only variants mapping to coding 438 exons of hg19 RefSeq transcripts. Plink/SEQv1.0 16 was used to run gene-wise burden 439 testing with a MAF<1% threshold. A 5% false discovery rate was used for multiple testing 440
correction. 441 442
Common variant association tests 443
Imputed data were filtered to include variants with MAF>1% and SNPTEST 2.5.2 46 was 444 used to test for associations across the region spanning the encoded gene. Bonferroni 445 correction was used for 3,000 tests across the loci (q=1.66E-5). Absorbance was normalized to the maximum peak of each sample. 476
In silico protein structure prediction 477
The web-based service Protein Homology/AnalogY Recognition Engine (Phyre2) 47 
